Semaglutide News and Research

Latest Semaglutide News and Research

Glycogen metabolism in neurons emerges as key to fighting Alzheimer's

A new study from scientists at the Buck Institute for Research on Aging has revealed a surprising player in the battle against Alzheimer's disease and other forms of dementia: brain sugar metabolism.

1 Jul 2025

Coffee’s hidden compounds could help fight type 2 diabetes

A comprehensive review of nearly 150 studies reveals that coffee polyphenols may help regulate blood sugar and reduce inflammation linked to type 2 diabetes. However, most evidence comes from preclinical research, and robust clinical trials are needed to confirm benefits.

29 Jun 2025

Tummy tuck patients continue losing weight years after surgery

Most patients undergoing "tummy tuck" surgery (abdominoplasty) to remove excess skin and tissue after weight loss continue to lose weight in the months and years after surgery, suggests a follow-up study in the July issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS).

26 Jun 2025

Tirzepatide rewires appetite and slashes calorie intake in new obesity trial

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain imaging revealed that tirzepatide also lowered neural responses to high-fat, high-sugar food cues, offering mechanistic insight into its potent weight-loss effects.

25 Jun 2025

New guidance helps GPs manage patients using weight loss drugs

Academics at King's College London and the University of East Anglia have released guidance for GPs on how to manage patients who may be privately accessing weight loss drugs.

25 Jun 2025

Once-monthly obesity injection shows double-digit weight loss in major clinical trial

Researchers found that once-monthly maridebart cafraglutide led to substantial weight loss and improved glycemic control in adults with obesity, with or without diabetes, in a phase 2 randomized trial. The drug demonstrated an acceptable safety profile and supports further study in phase 3 trials.

24 Jun 2025

Diabetes drug semaglutide shows promise in reducing dementia risk

Researchers at the Case Western Reserve School of Medicine have found that semaglutide, a popular diabetes and weight-loss drug, may lower the risk of dementia in people with type 2 diabetes (T2D).

24 Jun 2025

Experimental drug promotes weight loss by heating fat instead of suppressing appetite

An article published in the journal Nature Metabolism presents an experimental drug that stimulates adipose tissue cells to produce heat through a process known as thermogenesis, thereby promoting weight loss.

24 Jun 2025

Clinical trial finds new benefits of semaglutide for adults with type 1 diabetes

A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar and leads to substantial weight loss in adults with Type 1 diabetes who use automated insulin delivery systems.

23 Jun 2025

Cagrilintide and semaglutide together drive record weight loss in global trial

A 68-week phase 3 trial found that coadministered cagrilintide and semaglutide led to significant and clinically meaningful weight loss in adults with obesity but no diabetes. The combination outperformed either drug alone and improved multiple cardiometabolic health markers.

23 Jun 2025

Amycretin delivers unprecedented weight loss in early trial for obesity treatment

Once-weekly amycretin, a novel peptide activating GLP-1, amylin, and calcitonin receptors, produced rapid, substantial, and sustained weight loss in adults with overweight or obesity during a phase 1b/2a trial. The treatment was generally well tolerated, with mostly mild to moderate gastrointestinal side effects, supporting further investigation in larger, longer studies.

23 Jun 2025

New oral drug shows promise for type 2 diabetes and obesity without side effects

Lower blood sugar and increased fat burning – without negatively affecting appetite or muscle mass. These are some of the most promising effects of a new potential drug treatment for people with type 2 diabetes and obesity, according to a new study published in the journal Cell by researchers from Karolinska Institutet and Stockholm University.

23 Jun 2025

Diabetes medication shows promise in cutting migraine days by more than half

A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new study presented today at the European Academy of Neurology (EAN) Congress 2025.

20 Jun 2025

New ACC guidance helps incorporate pharmacologic weight management strategies into cardiovascular care

The American College of Cardiology has issued a Concise Clinical Guidance (CCG) document to aid clinicians in the use of medication for weight management in patients where treatment may provide cardiovascular benefit.

20 Jun 2025

How early-life factors raise lifelong diabetes risks in youth

The surge in diabetes among young people highlights critical gaps in care and the urgent need for comprehensive preventative actions to address this crisis.

19 Jun 2025

Oxytocin stimulates pancreatic hormones to improve insulin secretion

A new research paper was published in Aging (Aging-US) Volume 17, Issue 5, on May 1, 2025, titled "Oxytocin modulates insulin and GLP-1 secretion in pancreatic islets."

18 Jun 2025

Bariatric surgery linked to lower risk of psychiatric disorders than GLP-1 drugs

People who have metabolic and bariatric surgery are significantly less likely to develop psychiatric disorders compared to those who take weekly injections of GLP-1 anti-obesity medications, according to a new study presented today at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2025 Annual Scientific Meeting.

17 Jun 2025

Bariatric surgery leads to greater weight loss than GLP-1 drugs after two years

Sleeve gastrectomy and gastric bypass were associated with about five-times more weight loss than weekly injections of GLP-1 receptor agonists semaglutide or tirzepatide, at the end of two years, according to a new head-to-head real-world study presented today at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2025 Annual Scientific Meeting.

17 Jun 2025

Could a diabetes drug be the key to stopping Alzheimer’s?

Investigating tirzepatide's role in Alzheimer's reveals its potential to improve brain function and reduce inflammation, linking diabetes and neurodegeneration.

17 Jun 2025

Uncovering unexpected impacts of popular GLP-1 diabetes drugs

GLP-1 drugs show promise in diabetes management, offering heart and kidney benefits, but also highlight the need for vigilance regarding new health risks.

17 Jun 2025